Making a difference to the people we help treat by creating value and improving healthcare outcomes through connecting innovative manufacturers with Australasian customers.

The latest Analyte Quarterly update is here!

Products are for professional/laboratory use only. With a comprehensive list of new Single Molecule Counting (SMC™), ELISA and SARS-CoV-2 kits, along with new instruments and xMAP® INTELLIFLEX Calibration and verification kits for RUO.

 

 
 

The NEW update includes Single Molecule Counting (SMC™), MILLIPLEX®, and ELISA Kits, and reagents

 

 

 

 

 

MILLIPLEX® Panels    
MILLIPLEX® Immuno-Oncology Checkpoint Protein Panel 1 Mouse MCKP1-110K

 

SMC™ Kits    
SMC™ Total Tau High Sensitivity Immunoassay Kit Human 03-0185-00
SMC™ NGFβ High Sensitivity Immunoassay Kit (MTO*) Human 03-0200-00
SMC™ GFAP High Sensitivity Immunoassay Kit Human 03-0203-00
SMC™ IgM High Sensitivity Immunoassay Kit Human 03-0204-00

 

Conferma™ ELISA Kits    
IL-6 Conferma™ ELISA Human EZIL6-98K
IL-8 Conferma™ ELISA Human EZHIL8-100K
MCP-1 Conferma™ ELISA   Human EZMCP1-99KRM

 

SARS-CoV-2 ELISA Kits
Anti-RBD IgG Human ELISA Human EZRBDG-110K
Anti-RBD IgM Human ELISA Human EZRBDM-120K
Anti-S1 IgG Human ELISA Human EZS1G-130K
Anti-S1 IgM Human ELISA Human EZS1M-140K

Research Use Only. Not for use in Diagnostic procedures.

Find out more

Download Brochure>



Request a Quote

Request Quote

Recent Posts

Roche – New KAPA NGS Reagents

Roche KAPA kits offer a range of high-performance products for molecular biology applications in next-generation sequencing (NGS). KAPA RNA EvoPrep Kit The KAPA RNA EvoPrep…

Read full article

2027 Abacus dx Emerging Investigators Grant

COMING SOON Grant in Research Funding Empowering the Next Generation of Scientific Leaders Stay tuned for the 2027 Abacus dx Emerging Investigators Grant. More information…

Read full article

Developing Diagnostic Kits for Ovarian Cancer

In Australia, ovarian cancer is the deadliest reproductive cancer. The average five‑year survival rate sits at around 49%, compared with about 92% for breast cancer,…

Read full article